Levels of Antinuclear and Anti-double Stranded Antibodies in Sera of Breast Cancer Patients



  • Sadeq K. Hachim Department of Nursing Technology, Middle Technical University, Institute of Medical Technology,Baghdad, Iraq
  • Aesha S. Ali Department of Microbiology, College of Medicine, Ninevah University, Ninevah, Iraq
  • Mohammed R. Ali Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq


Autoantibodies, ADSAD, ANA, Biomarker, Breast cancer


Antinuclear antibodies (ANAs) and anti-double stranded deoxyribonucleic acid antibodies (ADSADs) are autoantibodies that have been linked to biomarkers of systemic autoimmune diseases. Although their involvement in relation to breast cancer is yet to be examined. Therefore, this study evaluated the serum  concentration of ANAs and ADSDAs in breast cancer patients, with a view to finding diagnostic biomarkers. One hundred female patients with breast cancer which were recently diagnosed depending on histopathology and hormonal receptor criteria by an oncologist, and another twenty-five females as healthy control group were recruited for the study. Direct interview of the female patients and healthy (control) group was conducted in addition to the information from patients’ registration records in the hospital. An aliquot of 5 mL of intravenous blood was collected from each subject to recover serum samples after centrifugation. An enzyme-linked immunosorbent assay (ELISA) was used to measure the concentrations of ANAs and ADSADs in the sera. The mean age of breast cancer patients was 55.60 years, while that of the healthy control group was 56.76 years.  here was a highly significant (P < 0.05) association between ANA of breast cancer patients and grade, as well as stage (MCP < 0.01). On the contrary, the concentration of ADSADs was showing no significant association with the grade (MCP > 0.05) and stage (MCP > 0.05) of breast cancer patients. Conclusively, our findings suggest the use of ANA as a diagnostic biomarker for breast cancer patients. 


Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP. Anti‑dsDNA antibodies and disease classification in

antinuclear antibody positive patients: The role of analytical diversity. Ann Rheum Dis. 2004; 63:386-394.

Pisetsky DS. Antinuclear antibody testing–misunderstood or misbegotten? Nat Rev Rheumatol. 2017; 13:495-502.

Robertson JM and James JA. Preclinical systemic lupus erythematosus. Rheum Dis Clin North Am. 2014; 40:621-635.

Madrid FF, VandeVord PJ, Yang X, Robert LK, Pippa MS, Michael JK, Jose LG, John ET. Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res. 1999; 5(1):393-400.

Madrid FF, Karvonen RL, Ensley J, Michael J, Michael K,Jose LG, Huda A, Naimei T, John ET. Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck. Cancer Detect Prev. 2005; 29:59-65.

Imran A, Neelam F, Tariq M. Incidence of circulating antinuclear antibodies in cancer patients. Indian J Med Sci. 2003; 57:113-116.

Pavlovic M, Kats A, Cavallo M, Chen R, Hartmann JX, Shoenfeld Y. Pathogenic and epiphenomenal anti ‑ DNA antibodies in SLE. Autoimmune Dis. 2010; 2011:462841.

Attar SM and Koshak EA. Medical Conditions associated with a positive anti-double-stranded deoxyribonucleic acid.

Saudi Ned J. 2010; 31:781-787.

Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017; 50:33.

Griffiths C and Brock A. Twentieth century mortality trends in England and Wales. Office for National Statistics. Health Stat Q. 2003; 18:5-17.

Mohammad DO and Najim RH. Relation of anti‑nuclear antibodies with 11 different types of cancer. Tikrit J Pharma

Sci. 2011; 7:51-54.

Madrid FF, Maroun M, Olivero OA, Long M, Stark A, Grossman L, Bander W, Dong J, Burke M, Nanthanson SD,

Zarbo R, Chitale D, Chavez RZ, Peebles C. Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. BMC Cancer. 2015; 15:407.

Wasserman J, Glas U, Blomgren H. Autoantibodies in patients with carcinoma of the breast. Correlation with

prognosis. Clin Exp Immunol. 1975; 19:417-422.

Berg WA, Campassi C, Langenberg P, Sexton MJ. Breast imaging reporting and data system. inter-and intra-observer variability in feature analysis and final assessment. Am J Roentgenol. 2000; 174:1769-1777.

Qinghua C, Wei X, Zhenke W, Lin X, Kang L, Yiwei C, Sidong Xiong. Anti-double stranded DNA monoclonal antibody induced by tumor cell-derived DNA inhibits growth of tumor in vitro and in vivo via triggering apoptosis. DNA Cell Biol. 2008; 27:91-100.




How to Cite

Hachim, S. K., Ali, A. S., & Ali, M. R. (2021). Levels of Antinuclear and Anti-double Stranded Antibodies in Sera of Breast Cancer Patients: doi.org/10.26538/tjnpr/v5i1.6. Tropical Journal of Natural Product Research (TJNPR), 5(1), 62–65. Retrieved from https://tjnpr.org/index.php/home/article/view/817